Monitor basophil degranulation and cell-signaling responses in whole blood samples using a leading flow cytometry workflow.
Basophil activation and degranulation measures allergy responses and immunotherapy efficacy. Our basophil activation test is performed directly on whole blood samples using the FlowCAST™ kit. Here, basophils are identified as SSCLOW and CCR3+, while the activation marker CD63 is used to investigate degranulation.
Our protocol has been validated for and implemented extensively in clinical trials, making it an excellent tool for exploratory and clinical studies.
Our BAT services have several clinical applications. This includes allergy clinical trials, where it can measure allergy severity and monitor acquisition of tolerance towards allergens, and as a surrogate pharmacodynamic marker to measure the effects of compounds targeting the degranulation pathway.
An expert partner with the clinical experience to support it.
Cutting-Edge Platform
Analytical Capabilities
Global Execution
Clinical Implementation
Immune Expertise
Our flow cytometry and cell-based assays extends from immune profiling to analysis.
Characterize complex immune cell subsets using off-the-shelf or fully customized panels.
Detect cytokine production at the single-cell level to profile immune function.
Advanced flow cytometry analysis and data visualization with incredible speed.
The basophil activation test is a clinical and exploratory assay performed on whole blood samples using flow cytometry. It specifically investigates degranulation markers, which can be used to measure allergy severity, monitor tolerance towards allergens, and observe clinical response to immunomodulatory treatments over time.
At CellCarta, we use the FlowCAST™ test in whole blood samples, identifying basophils as SSCLOW and CCR3+, while using CD63 as a reliable activation marker.
Yes. In addition to its use in allergy clinical trials, the basophil activation test can serve as a surrogate pharmacodynamic (PD) marker to monitor the effect of compounds targeting the degranulation pathway and protein tyrosine kinases such as SYK. This makes the basophil test applicable across immunology and oncology drug development programs targeting these pathways.
CellCarta uses the FlowCAST™ kit combined with its flow cytometry platforms to investigate basophil activation. Our basophil lab test define basophils as SSCLOW and CCR3+ and the activation marker CD63 is used to investigate degranulation.
